Aldose Reductase Inhibitor-Diabetes Complications Trial (ADCT)

INTERVENTION: Epalrestat(50mg) was orally administered three times daily before each meal (150 mg/day) with conventional therapies Conventional therapy (diet treatment, hypoglycemic agents, insulin, and hypotensive agents) CONDITION: Diabetic peripheral neuropathy PRIMARY OUTCOME: Change from baseline in median MNCV at 3 years SECONDARY OUTCOME: Other somatic nerve function parameters (minimum F‐wave latency [MFWL] of the median motor nerve and vibration perception threshold [VPT]), cardiovascular autonomic nerve function and subjective symptoms INCLUSION CRITERIA: Adults aged =>20 years were diagnosed in each facilities as mild diabetic peripheral neuropathy based on subjective symptoms, no foot ulcer and neurological dysfunctions (at least two parameters; MNCV [indispensable] and VPT or Achilles tendon reflex, etc.). Patients were enrolled for study if they had a median motor nerve conduction velocity (MNCV) =>40 m/s (seemingly reversible) and stable glycemic control (HbA1c <=9%, with +/‐ 0.5% variation in the previous 3 months).